 | • レポートコード：MRC2301D004 • 出版社/出版日：Transparency Market Research / 2022年10月28日 • レポート形態：英文、PDF、192ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査書では、世界の急性リンパ性白血病（ALL）市場について調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、種類別（B細胞性急性リンパ性白血病（ALL）、T細胞性急性リンパ性白血病（ALL））分析、治療法別（化学療法、放射線療法、骨髄移植、標的治療、免疫療法）分析、エンドユーザー別（病院、診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を整理しました。並びに、当書に掲載されている企業情報には、Amgen, Inc.、Bristol-Myers Squibb Company、Celgene Corporation、Erytech Pharma, Inc.、F. Hoffmann-La Roche Ltd.、Kite Pharma, Inc.、Novartis AG、Pfizer, Inc.、Sanofi、Spectrum Pharmaceuticals, Inc.などが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の急性リンパ性白血病（ALL）市場規模：種類別 - B細胞性急性リンパ性白血病（ALL）の市場規模 - T細胞性急性リンパ性白血病（ALL）の市場規模 ・世界の急性リンパ性白血病（ALL）市場規模：治療法別 - 化学療法の市場規模 - 放射線療法の市場規模 - 骨髄移植の市場規模 - 標的治療の市場規模 - 免疫療法の市場規模 ・世界の急性リンパ性白血病（ALL）市場規模：エンドユーザー別 - 病院における市場規模 - 診療所における市場規模 - その他エンドユーザーにおける市場規模 ・世界の急性リンパ性白血病（ALL）市場規模：地域別 - 北米の急性リンパ性白血病（ALL）市場規模 - ヨーロッパの急性リンパ性白血病（ALL）市場規模 - アジア太平洋の急性リンパ性白血病（ALL）市場規模 - 中南米の急性リンパ性白血病（ALL）市場規模 - 中東・アフリカの急性リンパ性白血病（ALL）市場規模 ・競争状況 |
Acute Lymphoblastic Leukemia Market – Scope of Report
TMR’s report on the global acute lymphoblastic leukemia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global acute lymphoblastic leukemia market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute lymphoblastic leukemia market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the acute lymphoblastic leukemia market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute lymphoblastic leukemia market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global acute lymphoblastic leukemia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute lymphoblastic leukemia market.
The report delves into the competitive landscape of the global acute lymphoblastic leukemia market. Key players operating in the global acute lymphoblastic leukemia market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute lymphoblastic leukemia market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market acute lymphoblastic leukemia.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Lymphoblastic Leukemia Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally
5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. B-cell Acute Lymphoblastic Leukemia
6.3.2. T-cell Lymphoblastic Leukemia
6.4. Market Attractiveness Analysis, by Type
7. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2017-2031
7.3.1. Chemotherapy
7.3.2. Radiation Therapy
7.3.3. Bone Marrow Transplant
7.3.4. Targeted Therapy
7.3.5. Immunotherapy
7.4. Market Attractiveness Analysis, by Treatment
8. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Acute Lymphoblastic Leukemia Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017-2031
10.2.1. B-cell Acute Lymphoblastic Leukemia
10.2.2. T-cell Lymphoblastic Leukemia
10.3. Market Value Forecast, by Treatment, 2017-2031
10.3.1. Chemotherapy
10.3.2. Radiation Therapy
10.3.3. Bone Marrow Transplant
10.3.4. Targeted Therapy
10.3.5. Immunotherapy
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Treatment
10.6.3. By End-user
10.6.4. By Country
11. Europe Acute Lymphoblastic Leukemia Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. B-cell Acute Lymphoblastic Leukemia
11.2.2. T-cell Lymphoblastic Leukemia
11.3. Market Value Forecast, by Treatment, 2017-2031
11.3.1. Chemotherapy
11.3.2. Radiation Therapy
11.3.3. Bone Marrow Transplant
11.3.4. Targeted Therapy
11.3.5. Immunotherapy
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Treatment
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Lymphoblastic Leukemia Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. B-cell Acute Lymphoblastic Leukemia
12.2.2. T-cell Lymphoblastic Leukemia
12.3. Market Value Forecast, by Treatment, 2017-2031
12.3.1. Chemotherapy
12.3.2. Radiation Therapy
12.3.3. Bone Marrow Transplant
12.3.4. Targeted Therapy
12.3.5. Immunotherapy
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Treatment
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Acute Lymphoblastic Leukemia Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. B-cell Acute Lymphoblastic Leukemia
13.2.2. T-cell Lymphoblastic Leukemia
13.3. Market Value Forecast, by Treatment, 2017-2031
13.3.1. Chemotherapy
13.3.2. Radiation Therapy
13.3.3. Bone Marrow Transplant
13.3.4. Targeted Therapy
13.3.5. Immunotherapy
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Treatment
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Lymphoblastic Leukemia Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. B-cell Acute Lymphoblastic Leukemia
14.2.2. T-cell Lymphoblastic Leukemia
14.3. Market Value Forecast, by Treatment, 2017-2031
14.3.1. Chemotherapy
14.3.2. Radiation Therapy
14.3.3. Bone Marrow Transplant
14.3.4. Targeted Therapy
14.3.5. Immunotherapy
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Treatment
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Bristol-Myers Squibb Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Celgene Corporation
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Erytech Pharma, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. F. Hoffmann-La Roche Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Kite Pharma, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Novartis AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Pfizer, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Sanofi
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Spectrum Pharmaceuticals, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis